Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. Chief Medical Officer Francine Kaufman reported a routine share disposition related to taxes. On the vesting of restricted stock units, 4,010 shares of common stock were withheld at a reference value of $7.18 per share to satisfy withholding tax obligations. After this tax-withholding event, Kaufman directly holds 177,057 shares of Senseonics common stock. This transaction does not represent an open-market purchase or sale, but an automatic mechanism to cover taxes tied to equity compensation.
Senseonics Holdings, Inc. Chief Operating Officer Mukul Jain reported a routine tax-related share disposition. On the Form 4, 16,194 shares of common stock at a value of $7.18 per share were withheld to satisfy withholding tax obligations when restricted stock units vested, rather than sold in the open market.
After this withholding, Jain directly holds 500,863 shares of Senseonics common stock. The transaction reflects compensation-related tax withholding and does not represent an open-market purchase or sale decision.
Senseonics Holdings, Inc. Chief Financial Officer Frederick T. Sullivan reported a routine tax-related share disposition. On the vesting of restricted stock units, 5,397 shares of common stock were withheld to satisfy withholding tax obligations, rather than sold on the open market.
After this tax-withholding disposition, Sullivan directly holds 226,477 shares of common stock. The filing reflects compensation-related share vesting mechanics, not an active purchase or sale decision in the market.
Senseonics Holdings, Inc. reported that GC & Corp. Development Advisor Kenneth L. Horton had 9,545 shares of common stock withheld on June 15, 2026 to cover tax obligations from vesting restricted stock units. After this tax-withholding event, he directly holds 285,512 common shares.
Senseonics Holdings, Inc. reported an insider equity update for Chief Commercial Officer Brian B. Hansen. On the reported date, 5,420 shares of common stock were disposed of at $7.18 per share to satisfy withholding tax obligations tied to vesting restricted stock units. This was a tax-withholding transaction rather than an open-market sale. After this event, Hansen directly owned 126,937 shares of Senseonics common stock.
Senseonics Holdings, Inc. reported an insider equity transaction by President and CEO Timothy T. Goodnow. On the reported date, 32,598 shares of common stock were withheld at a price of $7.18 per share to cover withholding tax obligations tied to the vesting of restricted stock units. This was not an open-market sale but a tax-withholding disposition. After this transaction, Goodnow directly held 1,143,748 shares of Senseonics common stock.
Senseonics Holdings, Inc. has completed the previously announced local asset purchase agreements with Ascensia Diabetes Care for its commercial Eversense continuous glucose monitoring (CGM) activities in several European markets. These transactions cover Eversense CGM commercial assets in Germany, Spain, Sweden and Italy.
The asset purchases in Germany, Spain and Sweden closed on June 1, 2026, and the purchase related to Italy closed on June 8, 2026, with the transfer effective for finance and accounting purposes as of June 1, 2026. This shifts ownership of these commercial assets from Ascensia to Senseonics and its affiliates in the covered countries.
Senseonics Holdings, Inc. reported that Chief Medical Officer Francine Kaufman received equity-based compensation on May 19, 2026. She was granted 63,177 restricted stock units, each representing a contingent right to one share of common stock. Following this grant, she holds 181,067 common shares directly.
She was also awarded an employee stock option for 86,935 shares of common stock at an exercise price of $5.54 per share, expiring on May 18, 2036. The RSUs vest in eight equal installments beginning June 15, 2026, while the options vest in 48 equal monthly installments starting May 19, 2026, in each case subject to her continued service.
Senseonics Holdings, Inc. reported that GC & Corp. Development Advisor Kenneth L. Horton received equity awards as part of his compensation. He was granted 157,943 restricted stock units (RSUs), each representing a right to receive one share of common stock. These RSUs vest in eight equal installments, starting on June 15, 2026, with the remaining seven installments vesting every six months beginning November 15, 2026, contingent on his continuous service.
Horton was also granted 217,338 employee stock options to buy common stock at an exercise price of $5.54 per share, expiring on May 18, 2036. These options vest in 48 equal monthly installments beginning on May 19, 2026, also subject to continued service. After these awards, he directly holds 295,057 shares of common stock and 217,338 options.
Senseonics Holdings, Inc. Chief Operating Officer Mukul Jain reported equity awards consisting of restricted stock units and stock options. He received 270,759 RSUs, each representing one share of common stock, and 372,579 employee stock options with an exercise price of $5.54 per share.
The RSUs vest in eight equal installments, starting on June 15, 2026, then every six months beginning November 15, 2026, subject to his continued service. The options vest in 48 equal monthly installments beginning May 19, 2026 and expire on May 18, 2036, also contingent on continued service. After the RSU grant, Jain directly holds 517,057 shares of common stock.